A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Clomiphene (CLOMID)

Estrogen Agonist/Antagonist class · 6 generic manufacturers · 6 ANDAs filed at FDA.

First FDA approval2022-09-09
Generic availableYes · 6 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.4M in CY2024 Part D spend7K claims · 2K beneficiaries · 329 plans surveyed

Lowest NADAC
$6.64/unit
12 NDCs benchmarked, lowest of all strengths.
Average NADAC
$7.40
Across all dosage forms in distribution.
Highest NADAC
$11.16
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Clomiphene used for?

Clomiphene is a Estrogen Agonist/Antagonist medication tracked in Medicare Part D.

Is there a generic for Clomiphene?

Yes. 6 ANDAs filed at FDA, 6 generic manufacturers currently shipping.

How much does my plan pay for Clomiphene?

Across 329 Part D plans, Clomiphene averages $7.40/unit (NADAC). Lowest available: $6.64/unit. Highest in distribution: $11.16/unit.

Is Clomiphene on the FDA shortage list?

No. Clomiphene is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Estrogen Agonist/Antagonist3 alternatives in D1
01
Ospemifene
Brand: Osphena
$8.16Lowest NADAC
0Generic mfrs
$11.4MCY24 Part D spend
Compare →
02
Raloxifene
Brand: Evista
$0.248Lowest NADAC
8Generic mfrs
$48.7MCY24 Part D spend
Compare →
03
Tamoxifen
Brand: SOLTAMOX
$0.139Lowest NADAC
5Generic mfrs
$16.0MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (12 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.